The use of pembrolizumab as a third line treatment for patients with PD-L1 positive (CPS ≥ 1) gastric adenocarcinoma is based on many important clinical trials (77), which are described in Table 1. This evidence concerns the gene CD274 and gastric adenocarcinoma.